Skip to main content
Erschienen in: Virology Journal 1/2023

Open Access 01.12.2023 | Research

Dysregulation of intracellular redox homeostasis by the SARS-CoV-2 ORF6 protein

verfasst von: Marta De Angelis, Gabriele Anichini, Anna Teresa Palamara, Lucia Nencioni, Gianni Gori Savellini

Erschienen in: Virology Journal | Ausgabe 1/2023

Abstract

SARS-CoV-2 has evolved several strategies to overcome host cell defenses by inducing cell injury to favour its replication. Many viruses have been reported to modulate the intracellular redox balance, affecting the Nuclear factor erythroid 2-Related Factor 2 (NRF2) signaling pathway. Although antioxidant modulation by SARS-CoV-2 infection has already been described, the viral factors involved in modulating the NRF2 pathway are still elusive. Given the antagonistic activity of ORF6 on several cellular pathways, we investigated the role of the viral protein towards NRF2-mediated antioxidant response. The ectopic expression of the wt-ORF6 protein negatively impacts redox cell homeostasis, leading to an increase in ROS production, along with a decrease in NRF2 protein and its downstream controlled genes. Moreover, when investigating the Δ61 mutant, previously described as an inactive nucleopore proteins binding mutant, we prove that the oxidative stress induced by ORF6 is substantially related to its C-terminal domain, speculating that ORF6 mechanism of action is associated with the inhibition of nuclear mRNA export processes. In addition, activation by phosphorylation of the serine residue at position 40 of NRF2 is increased in the cytoplasm of wt-ORF6-expressing cells, supporting the presence of an altered redox state, although NRF2 nuclear translocation is hindered by the viral protein to fully antagonize the cell response. Furthermore, wt-ORF6 leads to phosphorylation of a stress-activated serine/threonine protein kinase, p38 MAPK, suggesting a role of the viral protein in regulating p38 activation. These findings strengthen the important role of oxidative stress in the pathogenesis of SARS-CoV-2 and identify ORF6 as an important viral accessory protein hypothetically involved in modulating the antioxidant response during viral infection.
Hinweise
Lucia Nencioni and Gianni Gori Savellini have equally contributed.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Background

Coronaviruses (CoVs) are single-stranded, positive-sense RNA viruses with a large genome comprising the open reading frames (ORFs) 1a and 1b. These ORFs encode two polyproteins that are proteolytically cleaved into 16 non-structural proteins (Nsp1–16) which play crucial roles in the CoV life cycle [13]. In addition to structural and Nsp proteins, the CoV genomes also contain information for accessory proteins, encoded by ORFs located at the 3’-end, which are mainly involved in regulating the host’s response to infection [13]. Since the virus outbreak at the end of 2019 [4, 5], several virus variants have been reported, including the more recent BQ.1.1, BF.7, and XBB Omicron sub-lineages [69]. Differences in virus replication rates have been observed for these variants, suggesting the involvement of factors beyond host cell recognition [1014]. Viruses, including SARS-CoV-2, exploit various host cell pathways to support their replication and evade host defenses, such as suppressing immune responses [1520]. Oxidative stress is a biological process characterized by an imbalance between oxidant and antioxidant molecules within cells, leading to the overproduction of Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS), causing cellular damage [2125]. Viral infections disrupt the intracellular redox microenvironment, resulting in increased ROS production [26]. Nuclear factor erythroid 2-Related Factor 2 (NRF2) is the master transcription factor responsible for the activation of antioxidant response, protecting cells from oxidative stress and injury. Several respiratory viruses, including human Respiratory Syncytial Virus (RSV) [2729], Influenza virus (IV) [30], and Coronaviruses (CoVs) [3136], have been reported to modulate the redox state, affecting NRF2-mediated antioxidant response [3740]. For instance, studies on IV have shown that reduced glutathione (GSH) levels decrease during infection, leading to an imbalance in NOX4-mediated ROS production, which activates p38 and ERK Mitogen-Activated Protein Kinase (MAPK), promoting the nuclear export of viral ribonucleoprotein [4143]. Moreover, IV infection downregulates NRF2 gene expression and its nuclear translocation [30]. Other studies have highlighted the potential impact of oxidative stress on SARS-CoV-2 infection, suggesting that the overproduction of ROS and an impaired antioxidant system play a significant role in SARS-CoV-2 pathogenesis and the severity of Acute Respiratory Distress Syndrome (ARDS) [4446]. Studies on COVID-19 patients have shown that severe illness is associated with lower GSH levels and higher ROS production than mild disease [32, 33]. Additionally, lung biopsies from patients with severe COVID-19 exhibit downregulation of NRF2-mediated gene expression [34], and in vitro and in vivo studies have indicated that SARS-CoV-2 infection inhibits GSH and increases its oxidative form, GSSG, leading to reduced NRF2 activity [33, 35]. Although the viral components involved in these mechanisms have not been fully investigated and characterized, recent research has shown that the SARS-CoV-2 Nsp14 protein is capable of modulating the host cellular redox state by interacting with Sirtuin 1 and 5 (SIRT1-5) [47, 48]. In this context, considering the relationship between NRF2 pathway and the innate immune response [49, 50] in the host protection against respiratory virus infections, we explore the role of SARS-COV-2 ORF6 accessory protein. ORF6 has been previously associated with the control of host innate immunity and inflammation by blocking the expression of type I interferons (IFN-β) and interleukin-6 (IL-6) by hindering mRNA migration from the nucleus to the cytoplasm for translation [51]. Indeed, ORF6 is able of binding and of inhibiting nucleopore complex (NPC) proteins, affecting mRNA export from the nucleus to the cytoplasm, leading to a shutdown of cellular protein synthesis. Given the correlation between inflammation, innate immunity, and the redox state, our hypothesis was that the ORF6 protein might be involved in the modulation of cellular antioxidant response. Our results clearly demonstrate that the ORF6 protein negatively impacts cell homeostasis, leading to a downregulation of NRF2 signaling, including the downstream Glucose-6-Phosphate Dehydrogenase (G6PD) and Heme-Oxygenase-1 (HO-1) detoxifying proteins. These results are a consequence of the overproduction of ROS caused by the ectopic expression of ORF6. However, this mechanism is unlikely to be associated with transcriptional events, as NRF2 and downstream NRF2-controlled target mRNAs are induced by ORF6-mediated cell perturbation. Furthermore, NRF2 activation through phosphorylation by the cellular p38 MAPK is not impaired by the presence of ORF6, although its nuclear translocation is hindered by the viral protein. Moreover, the ORF6 C-terminus is critical for protein function in controlling the cellular antioxidant response, as supported by evidence using two protein mutants, M58R and Δ61. While the M58R residue mutation drastically reduces protein activity, the deletion of the last amino acid D61 (Δ61) completely abrogates protein function on NRF2, as well as on IFN-β and IL-6, as previously described [51, 52].

Methods

Cells and chemicals

Human embryonic kidney HEK-293T cells (ATCC CRL-1573) and A549 cells (ATCC CCL-185) are cultured in Dulbecco’s modified Eagle’s medium (DMEM) (EuroClone, Milan, Italy) supplemented with 100 U/mL penicillin/streptomycin (HyClone Europe, Milan, Italy) and 10% heat-inactivated foetal bovine serum (FCS) (Lonza) at 37 °C. Transfections are performed using the GeneJuice Transfection Reagent (Merck Life Sciences, Milan, Italy) following the manufacturer’s instructions. Tert-Butylhydroquinone (tBHQ), MG-132 proteasome inhibitor and N-acetyl-cysteine (NAC) are purchased from Merck Life Science.

Plasmids

The HA-tagged SARS-CoV-2 wild-type and M58R ORF6 expression plasmids are kindly provided by Prof. A. García-Sastre (CEIRS program; NIAD Centers of Excellence for Influenza Research and Surveillance; Mount Sinai School of Medicine, New York), while plasmid encoding HA-tagged SARS-CoV-2 ORF6 deleted by the last amino-acid (ORF6-∆61) mutant was prepared by standard cloning procedures using a naturally occurring virus variant (GenBank accession numbers OP002141). The ∆61 ORF6 coding sequence was amplified by Reverse-Transcription (RT)-Polymerase Chain Reaction (PCR) from viral RNA purified by using the QIAamp viral RNA mini kit (Qiagen, Milan, Italy) and cloned in the pCAGGS-MCS plasmid, in frame with a C-terminal HA-tag, at the EcoRI and XhoI unique sites. Recombinant plasmids are verified by sequencing. The pARE reporter plasmids encoding Firefly luciferase downstream of the Antioxidant Responsive Elements (ARE) and the Renilla luciferase downstream of the constitutively active SV40 promoter (pSV40-RL) are purchased from Promega (Milan, Italy). The plasmid encoding FLAG-tagged NRF2 was a gift from Randall Moon (Addgene plasmid #36971).

Luciferase reporter assay

To study the wild-type (wt)- or mutated ORF6 protein activity towards pARE, HEK-293T or A549 (2 × 105/well) cells are seeded in 24-well plates, and after over-night (o/n) incubation, the cells are transfected with 0.2 μg and 0.02 μg of pARE and pRL reporter plasmids, respectively, alone or in combination with 0.1 μg of ORF6-expressing plasmids. Where indicated, cells are co-transfected with 0.05 μg of NRF2 encoding plasmid. The total transfected DNA amount was kept constant by using an empty plasmid. At 36 h post-transfections, where indicated, cells are treated with 10 μM tBHQ, 1 μM MG-132 or an equivalent volume of vehicle for an additional 12 h. Cells are collected, and luciferase activities are measured on lysates using the Dual-Luciferase reporter assay reagent (Promega) according to the manufacturer's instructions. The results are given as the mean fold change in ARE promoter activation ± standard deviation (SD) from at least three independent experiments. Where indicated, recombinant protein expression was verified by immunoblotting on 50 μg of total cell lysates by using anti-HA and anti-FLAG-M2 mouse monoclonal antibodies (Merck Life Sciences) and anti-actin as a loading control (Merck Life Sciences).

Subcellular fractionation

HEK-293T cells expressing wt-ORF6 or the corresponding variants are collected at 24 h post-transfection. Pure nuclear and cytoplasmatic fractions are obtained by using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce, Milan, Italy) following the manufacturer’s instructions. Cytoplasmic and nuclear fraction protein content was determined by BCA protein assay kit (Pierce, Milan, Italy) and stored at − 80 °C for further use.

Immunoblotting

A total of 50 µg of total proteins was boiled in Laemmlie sample buffer for 5 min, separated by SDS‒PAGE and transferred to a NitroBind nitrocellulose membrane (Santa Cruz Biotechnology, Heidelberg, Germany). After blocking with Intercept Blocking Buffer (LI-COR Biosciences, Germany), antioxidant proteins are detected following membrane incubation with anti-G6PD, anti-NRF2 (Cell Signaling Technologies, Milan, Italy), anti-SOD1, anti-HO-1 (Santa Cruz Biotechnologies, Milan, Italy), anti-p38 and phosphorylated p38 (Santa Cruz Biotechnologies, Milan, Italy), anti-phosphorylated NRF2 (Ser40) (Thermo Fisher Scientific, Milan, Italy), anti-PKC (Santa Cruz Biotechnologies, Milan, Italy) or anti GSK-3β (Santa Cruz Biotechnologies, Milan, Italy). Actin was used as a loading control. After being washed three times with PBS containing 0.05% Tween-20 (PBS-T), the membranes are incubated with IRDye800/680-labelled goat anti-mouse/rabbit secondary antibodies (LI-COR Biosciences, Germany). Membranes are analysed by Odyssey Infrared Imager, and integrated intensities of fluorescence are used for densitometry analysis by using ImageJ software.

Quantitative assessment (RT‒qPCR) of oxidative stress markers expression

A549 and HEK-293T cells are transfected with either empty vector or plasmids expressing wild-type or mutant ORF6 variants as previously described. Cells are collected 24 h later, and total cellular RNA was isolated using the RNAeasy PLUS mini kit (Qiagen, Milan, Italy) following the manufacturer’s recommendations. Afterwards, the quality and quantity of the extracted RNA was verified by spectrophotometric reads, and equal amounts of RNA are subjected to a Reverse-Transcription quantitative PCR (RT‒qPCR) with SensiFAST reversion transcription kit and SensiFAST SYBR No-ROX PCR kit (Bioline) for cDNA synthesis and Nuclear factor erythroid 2-related factor 2 (NRF2), Glucose-6-phosphate dehydrogenase (G6PD) and Heme Oxygenase 1 (HO-1) gene expression analysis. Specific primers are available upon request. 18S rRNA was used as an internal control for amplification and normalization. The fold change in specific mRNA content was calculated relative to the mock, empty plasmid, transfected cells by the 2−∆∆Ct algorithm. The results are provided as the mean fold change from at least four independent experiments ± standard deviation.

Glutathione assay

GSH levels are quantified in transfected A549 cells collected at 24 h and 48 h post-transfection by using the Glutathione Assay Kit (Enzo Life Sciences, Milan, Italy) following the manufacturer’s instructions. Total GSH was quantified in cell lysates after deproteinization with metaphosphoric acid. Briefly, an aliquot of deproteinized samples was first incubated with 2-vinylpyridine to derivatize GSSG. Reduced GSH levels are calculated by differences between total GSH and GSSG and normalized to the protein content of each sample determined by the Bradford method (Bio-Rad, Milan, Italy). The results are provided as the mean fold change in GSH content ± standard deviation from at least three independent experiments.

Measurement of the intracellular ROS level

2′,7′-Dichlorofluorescin diacetate (H2DCFDA)-based (Merck Life Sciences) assays are used to detect the accumulation of intracellular reactive oxygen species (ROS) in A549 transfected cells. Briefly, A549 cells mock-transfected or expressing the wild-type or mutated ORF6 proteins are treated at 48 h post-transfection with 50 μM DCFDA or vehicle diluted in complete phenol red-free culture medium for 30 min at 37 °C. After extensive washes with phosphate-buffered saline (PBS), the generation of highly fluorescent 2',7'-dichlorofluorescein (DCF) was evaluated by microscopy (Eclipse Ts2, Nikon, Florence, Italy). For quantitative detection of DCF, fluorescence intensities are measured at 485/535 nm (excitation/emission) in a VICTOR™3 microplate reader (Perkin Elmer).

Statistics

The mean differences are statistically analysed by means of Mann Whitney U test among different study groups. Statistical significance was set at p < 0.05, two-tailed.

Results

SARS-COV-2 ORF6 modulates intracellular ROS production

SARS-CoV-2 has been reported to trigger Reactive Oxygen Species (ROS) production during viral infection [44]. However, most research has focused on humans and animal in vivo models to evaluate altered cellular redox state during acute infection, frequently associated with severe clinical profiles. Conversely, little effort has been made to identify viral protein(s) involved in controlling these pathways. Therefore, we investigated whether the SARS-CoV-2 ORF6 protein, known for its antagonistic effect on several cellular processes, has the ability to modulate ROS production. In parallel, we also investigated the impact of ORF6 mutants to identify functional domains within the protein. Indeed, as previously demonstrated, the ORF6 C-terminus has a critical role in protein function. Therefore, the naturally occurring ORF6 mutant carrying the deletion of the last amino acid (ORF6-Δ61) and the methionine 58 mutant (M58R) ORF6 variants were included in the study [51, 52]. The impact of the ORF6 viral protein on intracellular ROS production was determined by utilizing the fluorescent dye DCF. A549 cells ectopically expressing wt-ORF6 or its mutant variants were collected 24 h post-transfection and then stained with H2DCFDA, a nonfluorescent molecule that becomes fluorescent (DCF) in the presence of ROS due to their reducing activity. Fluorescence microscopy examination of transfected cells shows that, compared to the empty plasmid transfected control, the DCF fluorescence is increased in cells expressing wt-ORF6. In contrast, cells expressing the M58R and the Δ61 mutants show minor, non-significant, variations in DCF production (Fig. 1A). These findings suggest that the ORF6 protein is associated with intense ROS generation, achieved by suppressing the cellular scavenger system. To better quantify the differences in ROS generation caused by the presence of ORF6 variants, the release of DCF was quantified by fluorescence measurements (Ex/Em: ∼492–495/517–527 nm) of the cell suspension. As reported in Fig. 1B, a mean fold increase of 1.68 ± 0.04 (p = 0.046) and 1.27 ± 0.13 (p = 0.021) is observed in cells ectopically expressing wt and M58R ORF6, respectively, whereas the presence of Δ61 protein variant does not affect cellular ROS content (fold change; 1.12 ± 0.12, p = 0.642). To further support the evidence that ORF6 is associated with the induction of oxidative stress, intracellular reduced glutathione (GSH) was quantified in transfected A549 cells. As reported in Fig. 1C, the presence of wt-ORF6 protein counteracts the physiological cellular response to the increased ROS at 24 h post-transfection, leading to a significant reduction in GSH of approximately 30% (mean fold change 0.71 ± 0.15; p = 0.02). In contrast, the expression of the M58R ORF6 mutant is not associated with altered intracellular GSH content (1 ± 0.19; p = 0.063), while Δ61 mutant lead to the activation of the GSH-based detoxifying cellular system (mean fold change 1.45 ± 0.22; p = 0.002) (Fig. 1C).

SARS-CoV-2 ORF6 hinders NRF2 activity to suppress the antioxidant response

The transcription factor Nuclear factor erythroid 2-related factor 2 (NRF2) plays a key role in activating the antioxidant response to counteract oxidative stress stimuli and ROS production occurring during viral infections. The recruitment of NRF2 at the Antioxidant Response Element (ARE) located in the promoter of many human genes, particularly those responsible for scavenging ROS, is essential for the induction of antioxidant enzymes and the establishment of an efficient detoxifying response. Studies conducted on Influenza A virus have shown the downregulation of NRF2 protein levels or its activation and the overproduction of ROS during infections [30]. Similarly, SARS-CoV-2 infection has been associated with a down-regulation of NRF2, although this mechanism has not been deeply investigated [3436, 47, 48]. Using a reporter assay in which the expression of the luciferase reporter gene is a consequence of ARE cis-element activation, we tested the antagonistic activity of the SARS-CoV-2 ORF6 protein on the NRF2 signaling pathway. In A549 epithelial lung cells, the ectopic overexpression of the wt-ORF6 protein concurs with the dramatic reduction in ARE-mediated luciferase expression, leading to a 3.6-fold reduction (fold change 0.27 ± 0.088; p = 0.019) in specific promoter activation (Fig. 2A). In contrast, the M58R ORF6 mutant, previously described as inactive towards nucleopore proteins hindrance, lose its antagonistic function on NRF2/ARE axis activation, with markedly reduced antagonistic activity (0.73 ± 0.13-fold promoter activation, p = 0.059) compared to the negative control (Fig. 2A). On the other hand, ORF6-Δ61 is completely incapable of hindering ARE promoter activation (fold change 0.98 ± 0.08; p = 0.642) (Fig. 2A). Similar results are obtained when we used the HEK-293T cell line to assess pARE activation. In this cell system, only wt-ORF6 demonstrates the ability to mediate repression of the indicated promoter, resulting in approximately a four-fold reduction in pARE activation (fold change 0.25 ± 0.04; p = 0.002), as depicted in Fig. 2A. To further support the antagonistic effects of the ORF6 protein on NRF2 signaling, its inhibitory activity towards ARE-containing promoter activation was investigated in a NRF2-stimulated system in which the antioxidant tert-Butylhydroquinone (tBHQ), which targets Keap1, and N-acetyl-cysteine (NAC), a well-known antioxidant compound, resulted in NRF2 hyper-activation. Since A549 alveolar epithelial cells present a mutation in the Keap1 gene, this cell system is insensitive to tBHQ and NAC [84]; thus, HEK-293T cells were used. The wt-ORF6 strongly counteracts both the tBHQ and NAC-inducible functions, reducing pARE activity by 12- and 4.8-fold, respectively (p = 0.006 and p = 0.02, respectively) (Fig. 2B). Conversely, the presence of the M58R mutant does not alter the tBHQ activity (fold change 0.95 ± 0.21; p = 0.877), while the Δ61-ORF6 variant exerts a costimulatory function on NRF2, leading to an up-regulation of pARE activity of 1.5-fold (p = 0.007) (Fig. 2B). Surprisingly, both ORF6 mutants have synergistic effects with NAC on the NRF2-ARE axis, since the antioxidant properties of the drug are augmented by more than four fold (p < 0.005) by viral protein expression (Fig. 2B). To address whether this antagonistic function is a consequence of ORF6 activity on newly synthesized mRNA movements to the cytoplasm, thus limiting cellular protein translation, or to a target-specific activity of the transcription factor, the pARE reporter assay was then assessed in HEK-293T cells over-expressing ectopic FLAG-tagged NRF2. Despite the small amount of transfected FLAG-NRF2 plasmid, the resulted protein sufficiently accumulates into the cells, as demonstrated by immunoblotting by using anti-FLAG epitope antibody (Fig. 2C, lower panel), and strongly stimulates ARE promoter activation, leading to a 16.4 ± 4.1 (p < 0.005) folds increase in pARE-mediated firefly luciferase expression (data not shown). The antagonistic property of wt- and M58R ORF6 on NRF2 is evidenced by a drastic decrease in the ectopic transcription factor content (Fig. 2C, lower panel) and, consequently, in pARE activation (fold change 0.26 ± 0.07; p = 0.021 and 0.64 ± 0.13; p = 0.02, respectively) (Fig. 2C). In contrast, and in agreement with previously results, the Δ61-ORF6 mutants is unable to counteract NRF2-mediated specific promoter activation even when the transcription factor is over-expressed (fold change 1.3 ± 0.47, p = 0.278) and its cellular accumulation is not perturbed (Fig. 2C). To examine the effects of ORF6 on NRF2 viability, we studied transcription factor activity in MG132-treated cells. Indeed, since NRF2 function is limited by Keap1 interaction and its subsequent ubiquitination and degradation, the MG-132 proteasome inhibitor behaves as an antioxidant increasing NRF2 cytoplasmic accumulation. Although proteasome inhibition by MG-132 is associated with an increase in NRF2 accumulation, perturbation of cellular homeostasis is also observed. However, in HEK-293T cells expressing the wt- or the M58R mutant ORF6 protein, the antagonistic behaviour of the viral protein towards pARE activation is not abolished by MG-132 (fold change 0.24 ± 0.018; p = 0.019, 0.69 ± 0.021; p = 0.039 respectively) (Fig. 2C). Instead, the activity of the Δ61 mutated ORF6 variant is not altered (p = 0.059) by the presence of the inhibitor. Furthermore, immunoblotting detection of ectopic FLAG-tagged NRF2 shows that its expression is significantly decreased in wt and, to a lesser extent, in M58R ORF6-expressing HEK-293T cells despite MG-132 treatment (fold change 0.12 ± 0.04; p = 0.019, 0.72 ± 0.04; p = 0.039) (Fig. 2D). In contrast, NRF2 protein is equally accumulated in the cytoplasm of control cells and ∆61-ORF6 variant-containing cells (Fig. 2D). It's important to note that, while MG-132 treatment is expected to increase protein accumulation by reducing their turnover through the ubiquitin–proteasome system, the drug may also have broader effects on general protein translation and cell proliferation. This is evident from the observed decrease in NRF2 content in all samples exposed to MG-132. However, these results further underline the activity of the viral protein on the NRF2 translational process rather than on mature NRF2 protein turnover.

Transcriptional control of the NRF2 pathway is not impaired by ORF6

The transactivation of promoters containing the ARE consensus sequence and antioxidant gene expression is regulated by binding of the transcription factor NRF2 to the mentioned promoter regions [37]. Based on our preliminary results, to further investigate whether ORF6 impacted the antioxidant cellular response mediated by NRF2, we quantified NRF2 mRNA in HEK-293T cells, harbouring an intact antioxidant system, after ectopic expression of the viral protein. RT‒qPCR analysis demonstrates that NRF2 mRNA expression is induced by wt or mutant ORF6 at 24 h post-transfection. The ectopic expression of wt-ORF6 induces a significant increase (p = 0.008) of almost twofold (1.9 ± 0.13) in NRF2 mRNA accumulation, whereas the M58R mutated protein leads to a modest (1.3 ± 0.05-fold induction) (p = 0.01) increase in NRF2-specific transcripts. Similarly, Δ61-ORF6 upregulates NRF2 expression at the transcriptional level (fold stimulation 1.8 ± 0.007; p = 0.019) (Fig. 3A). These data are further validated by evidence that Influenza virus PR/8 infection of cultured HEK-293T cells results in a transcriptional downregulation of NRF2 at early times of infection (24 h), leading to a decrease (fold expression 0.21 ± 0.03; p = 0.006) in specific mRNA content, as previously demonstrated in literature [30] (Fig. 3A). Accordingly, NRF2 modulation by ORF6 variants influences the expression of scavenger proteins, such as Glucose-6-Phosphate Dehydrogenase (G6PD) and Heme Oxygenase-1 (HO-1). Indeed, both detoxifying genes are significantly upregulated at the transcriptional level (p < 0.05) (fold change ~ 2 ± 0.22) by wt-ORF6 and both protein mutants (Fig. 3A). Moreover, Influenza virus PR/8 infection mediates 0.45 ± 0.01 (p = 0.005) and 0.25 ± 0.15 (p = 0.029) fold reduction in G6PD and HO-1 scavenger’s gene expression, respectively (Fig. 3A). The described ORF6 activity is further reported when the ectopic expression of the viral proteins is accomplished in A549 cells, although lower expression of the foreign proteins is observed in this cell line. Indeed, despite A549 transfected cells are widely used in in vitro experimental models of SARS-CoV-2 infection [53], the expression of NRF2-controlled genes might not reflect the physiological condition because of their Keap1 mutation [54]. Notwithstanding, this cell line has been used in several studies concerning redox state changes during viral infections, including ours [30]. In this study, we observe a significant induction of the NRF2 axis due to the presence of ORF6, wt- or mutated versions (Fig. 3B).

NRF2 is downregulated by ORF6 to maintain oxidative stress conditions

Previous results showed that the infection of both Calu-3 and Vero E6 cells by SARS-CoV-2 determines a downregulation of signaling proteins involved in cellular homeostasis and the antioxidant scavenger system [33, 35]. Olagnier and colleagues identified NRF2 as the major factor affected by virus infection and replication, leading to the suppression of NRF2-inducible proteins HO-1 and NAD(P)H quinone oxidoreductase-1 (NqO-1) [34]. Based on these evidences, we further analysed the expression pattern of antioxidant-related genes upon SARS-CoV-2 ORF6 ectopic expression in HEK-293T and A549 cells. In contrast to the mRNA expression profile reported above, the antioxidative response is significantly suppressed by the presence of wt-ORF6 at the protein level. We performed an immunoblot assay on HEK-293T whole-cell lysates (WCLs) to assess NRF2, G6PD, and HO-1 protein levels after SARS-CoV-2 ORF6 expression. We find that overexpression of viral wt-ORF6 significantly reduces endogenous NRF2 protein content by approximately 40% (p = 0.007), whereas neither the M58R (mean fold 1.16 ± 0.88, p = 0.11) nor the Δ61-ORF6 (mean fold 1.09 ± 0.16, p = 0.64) presence perturbs the physiological levels of NRF2 protein within the cell (Fig. 4A). In addition, the antioxidant effectors G6PD and HO-1, whose expression is regulated by NRF2, are markedly reduced (fold change 0.71 ± 0.10, p = 0.03; 0.61 ± 0.18, p = 0.012, respectively) when wt-ORF6 is expressed in HEK-293T cells (Fig. 4B). Instead, both M58R and ORF6-Δ61 have no significant impact on G6PD and HO-1 cytoplasmic accumulation (Fig. 4B), suggesting that the amino acid at the ORF6 C-terminus (D61) is involved in the observed NRF2 protein downregulation. To further confirm our findings, NRF2 protein expression was also assessed in A549 cells. In the new cellular system, a pronounced decrease in the transcription factor is observed when wt-ORF6 (fold change 0.52 ± 0.16; p = 0.012) is expressed. However, M58R does not display detectable activity toward NRF2 (fold change 0.95 ± 0.32; p = 0.08) (Fig. 4C). Conversely, the Δ61-ORF6 variant is completely inactive in down-regulating NRF2 protein content in A549 cells (fold change 2.6 ± 0.15; p = 0.005) (Fig. 4C).

NRF2 nuclear movement is hindered by ORF6

Based on our evidence demonstrating the downregulation of NRF2 protein mediated by wt-ORF6 and the M58R mutant, we further investigated NRF2 activation in the HEK-293T cell system. While NRF2 activity is mainly regulated by its turnover through Keap1-mediated ubiquitination and proteasomal degradation, it can also be regulated at the post-translational level. Phosphorylation at the serine, threonine or tyrosine residues in NRF2 may affect, both positively or negatively, the process of NRF2 proteasomal degradation, nuclear movement and binding to the ARE-containing promoter sequence [54]. In the present study, we mainly focused on NRF2 serine 40 (S40) phosphorylation since it has been reported to promote NRF2 dissociation from Keap1, thereby leading to increased nuclear translocation and transcription of ARE-driven antioxidant genes [55]. The immunoblotting performed on whole cell lysates of transfected HEK-293T cells shows a significant increase in S40 phosphorylated NRF2 (pNRF2) when both wt and M58R ORF6 are expressed (1.58 ± 0.23; p = 0.012, 1.51 ± 0.22; p = 0.012), in line with the previously described increase in ROS cytoplasmic accumulation, whereas the ∆61 mutant lead to a marginal, non-significant (1.02 ± 0.15, p = 0.083), activation of the transcription factor (Fig. 5A, upper panel). Data analysis based on the ratio between phosphorylated and total NRF2 content clearly shows a strong increase in pNRF2 when the wt and M58R ORF6 variants are present (2.9 ± 0.49; p = 0.002, 1.9 ± 0.29; p = 0.012), while the ∆61 protein fails to induce NRF2 activation (1.02 ± 0.2; p = 0.22) by phosphorylation (Fig. 5A, lower panel). Afterwards, the possible ORF6 hindrance of NRF2 nuclear translocation was assessed in nuclear fractions of HEK-293T cells expressing the wt-ORF6, M58R or ∆61 protein. As reported in Fig. 5B, wt-ORF6 only determines a decrease in nuclear NRF2 levels (fold change 0.61 ± 0.02; p = 0.005), which, consequently, is associated with a decrease in its phosphorylated form in the same cellular compartment (fold change 0.67 ± 0.01; p = 0.002) (Fig. 5B). In contrast, both the M58R and ∆61 ORF6 mutant proteins lead to marginal (fold change 0.86 ± 0.02; p = 0.22 and 0.87 ± 0.05; p = 0.22) variation in nuclear NRF2 content. Among them, only the ORF6-∆61 mutant is able to induce an increase in pNRF2 nuclear accumulation (1.3 ± 0.07; p = 0.002), which is better evidenced by the ratio between nuclear pNRF2/nuclear NRF2 (1.5 ± 0.04; p = 0.019). These results suggest that wt-ORF6 do not impair NRF2 activation by phosphorylation but rather down-regulates NRF2 accumulation in both nuclear and cytoplasmic compartments. Moreover, the reduced nuclear localization of pNRF2 compared to the cytoplasmic counterpart detected in both wt and M58R ORF6-expressing cells (0.42 ± 0.08; p = 0.005, 0.57 ± 0.03; p = 0.012) also confirms the hindrance by the viral protein of nuclear movement of the indicated transcription factor upon its cytoplasmic activation (Fig. 5C). As supporting evidence, the deleted ORF6 does not hinder pNRF2 translocation, since a 1.27 ± 0.07-fold increase (p = 0.005) in nuclear, active, NRF2 is noticed (Fig. 5C). HEK-293T transfected samples were further analysed to monitor the cellular levels of kinases that are known to be activated by oxidative stress stimuli and are involved in NRF2 modulation: Protein Kinase C (PKC), Glycogen Synthase Kinase 3-beta (GSK-3β), and p38 mitogen-activated protein kinases (MAPKs). Contrary to PKC activity, GSK-3β is observed to phosphorylate NRF2, inducing Cullin-1/Rbx1-mediated NRF2 ubiquitination and subsequent degradation [56], while the p38 MAPK has been reported to both positively and negatively regulate the NRF2-mediated antioxidant response [5761]. In our hands, the ORF6 reveals marginal control, although statistically significant, on PKC and GSK-3β cellular content (Fig. 6A). On the contrary, we observe that activated phosphorylated p38 (pp38), relative to total p38 protein level, is markedly increased in samples where wt-ORF6 (fold change 1.43 ± 0.02, p = 0.031) or M58R (fold change 1.73 ± 0.19, p = 0.005) is present, whereas the ∆61 protein variant is unable to upregulate kinase activity (fold change 0.75 ± 0.005, p = 0.063), suggesting a role for MAPKs in ORF6 activity toward NRF2 (Fig. 6B). These data agree with previous data showing NRF2 hyper-phosphorylation in both M58R- and wt-ORF6-expressing cells, while unperturbed pNRF2 levels are described for ∆61-ORF6 (Fig. 5A).

Discussion

There are many evidences that SARS-CoV-2, similar to its ancestors SARS-CoV and MERS-CoV, has evolved multiple mechanisms to overcome cellular pathways, including innate immunity and cellular oxidative stress, to elicit virus replication [16, 17, 44, 62, 63]. Some authors have depicted the importance of the antioxidant response during SARS-CoV-2 infection, both in vitro and in vivo, demonstrating the Nuclear factor erythroid 2-related factor 2 (NRF2) downregulation during viral infection [34]. Furthermore, Zhang et al. proposed the involvement of the NSP14 viral protein in the NRF2 pathway to control the cell response to infection [48]. Within virus accessory proteins, ORF6 has an important role in host immunity evasion by inhibiting the nuclear translocation of STAT1 and hindering nucleopore traffic of newly synthetized mRNAs to block IFN-β and other cytokines (e.g., IL-6) expression [51, 52, 64]. SARS-CoV-2 variants differ from the Wuhan-1 strain by genetic mutations, mostly located in the Spike protein, but also other viral proteins are affected by virus genetic evolution, determining mutations or deletions in both structural and non-structural proteins [6568]. Mutations outside the Spike protein are likely to contribute to virus pathogenicity, such those targeting the ORF6 which, by enhancing nuclear retention of newly synthetized mRNAs, allow the virus to escape from the immune system [51, 52, 64, 6668]. Among them, the ORF6 D61L substitution described for BA.2 and BA.4 Omicron sub-lineages influences viral protein function. Indeed, while the methionine 58 mutation (M58R), described as inactive with respect to the nucleopore complex hindrance, partially reverts the antagonistic properties of ORF6, the D61 deletion (ORF6-∆61) completely abrogated protein function. Therefore, the ORF6 impact on NRF2, which represents the master transcription factor involved in the cell antioxidant response and inflammation, deserves to be evaluated. In the present study, we demonstrate that SARS-CoV-2 ORF6 determines changes in cellular redox status, leading to a down-regulation of NRF2 and of the NRF2-induced detoxifying system, such as Heme Oxygenase-1 (HO-1) and Glucose-6-Phosphate Dehydrogenase (G6PD) scavengers. As a consequence, the lack of an efficient detoxifying response reported in wild-type (wt)-ORF6 ectopically expressing cells causes intracellular ROS accumulation and compromises the GSH/GSSG ratio. Conversely, the ectopic expression of C-terminal mutated ORF6 variants have minor or no effects. A plausible mechanism of action for ORF6 is issued by RT‒qPCR of messenger RNA for NRF2 and for its downstream scavenger genes that are accumulated following expression of the wt viral protein. We demonstrate that the ORF6 protein hinders host mRNA nuclear export and NRF2 protein translation to establish an unbalanced redox status, which is favourable for virus replication and spread, as described for many other viruses [30, 51]. Indeed, while the expression of the M58R and ∆61 protein mutants is negligible for endogenous NRF2 protein accumulation in both HEK-293T and A549 cells, the cytoplasmic protein level of NRF2 is markedly downregulated by wt-ORF6 expression. The antagonistic property of the wt-ORF6 viral protein on NRF2 is further confirmed by investigating the activation of Antioxidant Responsive Elements (ARE)-containing promoter (pARE) present in several antioxidant genes [69, 70]. The wt viral protein targets NRF2-dependent pARE activation, while the loss of activity of the M58R and ∆61 ORF6 mutants provides new evidence for SARS-CoV-2 counteracting strategies in host defences. Furthermore, neither the presence of a Keap1 inhibitor (tBHQ), the use of an NRF2 inducer (NAC) nor the overexpression of exogenous NRF2 are able to restore the transcriptional regulation of the ARE promoter when wt-ORF6 and, to a lesser extent, M58R is present. Furthermore, the proteasome inhibitor MG-132 fails to restore the levels of exogenous NRF2 when the wt-ORF6 protein is expressed, confirming that the reported decrease in the transcription factor content and downstream activity is not a consequence of its ubiquitin-dependent proteasomal degradation. NRF2 activity can also be regulated at post-translational level through phosphorylation by several kinases. Different kinases are associated with both positive and negative NRF2 regulation, including GSK-3β, PI3K/Akt, MAPKs, β-TrCP and PKC [7182]. In our hands, wt-ORF6 does not affect PKC and GSK-3β protein levels. Conversely, it induces an increase in phosphorylated, active, p38 MAPK, while the D61 deleted mutant fails to do so, suggesting a role of the C-terminal domain of ORF6 in regulating p38 MAPK activity. Overall, these results provide a new mechanism by which SARS-CoV-2 might modulate cell host homeostasis to favour its own replication and spread, and the present data are strikingly connected to previous observations about IFN-β hindrance by ORF6 [51]. In facts, a recent report demonstrated that NRF2 might be a natural regulator of IFN responses in airway epithelial cells [83] and we speculate that SARS-CoV-2 also takes advantage of the ORF6 protein to minimize the nuclear translocation of residual NRF2 and IFN-β response. This new knowledge supports clinical evidence of a role for oxidative stress in the pathogenesis of COVID-19 and opens the way to new therapeutic strategies, as the viral protein ORF6 represents one of the most important SARS-CoV-2 virulence factors acting as a multifunctional modulator of host cellular processes.

Conclusions

Oxidative stress has been highlighted in the pathogenesis of SARS-CoV-2 infection and is mainly defined by the overproduction of Reactive Oxygen Species (ROS) which, despite the negative impact on cell metabolism, supports viral replication. Since the mechanisms underlying SARS-CoV-2 pathogenesis are still unclear, we further investigated the activity of the ORF6 protein toward the cellular antioxidant response. Our data demonstrated the antagonistic activity of ORF6 on the transcription factor NRF2, which is associated with the expression of scavenger genes. Thus, ORF6 negatively modulated the cellular detoxifying response and supported the unbalanced cellular redox state, such as the GSH/GSSG redox sensing system. Furthermore, the hindrance of residual NRF2 movement to the nucleus is shown. In conclusion, the NRF2 axis represents a valid target to counteract cell damage induced by a compromised detoxifying system and the exacerbated inflammatory response triggered by the virus.

Declarations

This article does not contain any studies with human participants or animals performed by any of the authors.

Competing interests

The authors have no competing interests that might be perceived to influence the results and/or discussion reported in this paper. The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;2020(395):565–74. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;2020(395):565–74.
2.
Zurück zum Zitat Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165878.PubMedPubMedCentral Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165878.PubMedPubMedCentral
3.
Zurück zum Zitat Wu CR, Yin WC, Jiang Y, Xu HE. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Acta Pharmacol Sin. 2022;43:3021–33.PubMedPubMedCentral Wu CR, Yin WC, Jiang Y, Xu HE. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Acta Pharmacol Sin. 2022;43:3021–33.PubMedPubMedCentral
4.
Zurück zum Zitat Holmes EC, Goldstein SA, Rasmussen AL, Robertson DL, Crits-Christoph A, Wertheim JO, et al. The origins of SARS-CoV-2: a critical review. Cell. 2021;184:4848–56.PubMedPubMedCentral Holmes EC, Goldstein SA, Rasmussen AL, Robertson DL, Crits-Christoph A, Wertheim JO, et al. The origins of SARS-CoV-2: a critical review. Cell. 2021;184:4848–56.PubMedPubMedCentral
5.
Zurück zum Zitat WHO. 2020. Director-General’s opening remarks at the media briefing on COVID19. WHO. 2020. Director-General’s opening remarks at the media briefing on COVID19.
6.
Zurück zum Zitat Mannar D, Saville JW, Sun Z, Zhu X, Marti MM, Srivastava SS, et al. SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization. Nat Commun. 2022;13:4696.PubMedPubMedCentral Mannar D, Saville JW, Sun Z, Zhu X, Marti MM, Srivastava SS, et al. SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization. Nat Commun. 2022;13:4696.PubMedPubMedCentral
7.
Zurück zum Zitat Mohapatra RK, Sarangi AK, Kandi V, Azam M, Tiwari R, Dhama K. Omicron (B.1.1.529 variant of SARS-CoV-2); an emerging threat: Current global scenario. J Med Virol. 2022;94:1780–3.PubMedPubMedCentral Mohapatra RK, Sarangi AK, Kandi V, Azam M, Tiwari R, Dhama K. Omicron (B.1.1.529 variant of SARS-CoV-2); an emerging threat: Current global scenario. J Med Virol. 2022;94:1780–3.PubMedPubMedCentral
9.
Zurück zum Zitat Varghese R, Kumar D, Sharma R. Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern? Hum Cell. 2023;36:1218–21.PubMedCentral Varghese R, Kumar D, Sharma R. Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern? Hum Cell. 2023;36:1218–21.PubMedCentral
10.
Zurück zum Zitat Mautner L, Hoyos M, Dangel A, Berger C, Ehrhardt A, Baiker A. Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. Virol J. 2022;19:76.PubMedCentral Mautner L, Hoyos M, Dangel A, Berger C, Ehrhardt A, Baiker A. Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. Virol J. 2022;19:76.PubMedCentral
11.
Zurück zum Zitat Gori Savellini G, Anichini G, Cusi MG. SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells. Virus Res. 2023;332:199134.PubMedPubMedCentral Gori Savellini G, Anichini G, Cusi MG. SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells. Virus Res. 2023;332:199134.PubMedPubMedCentral
12.
Zurück zum Zitat Telenti A, Hodcroft EB, Robertson DL. The Evolution and Biology of SARS-CoV-2 Variants. Cold Spring Harbor Perspect Med. 2022;12:a041390. Telenti A, Hodcroft EB, Robertson DL. The Evolution and Biology of SARS-CoV-2 Variants. Cold Spring Harbor Perspect Med. 2022;12:a041390.
13.
Zurück zum Zitat Xia S, Wang L, Zhu Y, Lu L, Jiang S. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduct Target Ther. 2022;7:241.PubMedPubMedCentral Xia S, Wang L, Zhu Y, Lu L, Jiang S. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduct Target Ther. 2022;7:241.PubMedPubMedCentral
14.
Zurück zum Zitat Papanikolaou V, Chrysovergis A, Ragos V, Tsiambas E, Katsinis S, Manoli A, et al. From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. Gene. 2022;814:146134.PubMedPubMedCentral Papanikolaou V, Chrysovergis A, Ragos V, Tsiambas E, Katsinis S, Manoli A, et al. From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. Gene. 2022;814:146134.PubMedPubMedCentral
15.
Zurück zum Zitat Baggen J, Vanstreels E, Jansen S, Daelemans D. Cellular host factors for SARS-CoV-2 infection. Nat Microbiol. 2021;6:1219–32.PubMed Baggen J, Vanstreels E, Jansen S, Daelemans D. Cellular host factors for SARS-CoV-2 infection. Nat Microbiol. 2021;6:1219–32.PubMed
16.
Zurück zum Zitat Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036-1045.e9.PubMedPubMedCentral Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036-1045.e9.PubMedPubMedCentral
17.
Zurück zum Zitat Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20:397–8.PubMedPubMedCentral Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20:397–8.PubMedPubMedCentral
18.
Zurück zum Zitat Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24.PubMedPubMedCentral Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24.PubMedPubMedCentral
19.
Zurück zum Zitat Oh SJ, Shin OS. SARS-CoV-2 nucleocapsid protein targets RIG-I-like receptor pathways to inhibit the induction of interferon response. Cells. 2021;10:530.PubMedPubMedCentral Oh SJ, Shin OS. SARS-CoV-2 nucleocapsid protein targets RIG-I-like receptor pathways to inhibit the induction of interferon response. Cells. 2021;10:530.PubMedPubMedCentral
20.
Zurück zum Zitat Gori Savellini G, Anichini G, Gandolfo C, Cusi MG. SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity. Viruses. 2021;13:1439.PubMed Gori Savellini G, Anichini G, Gandolfo C, Cusi MG. SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity. Viruses. 2021;13:1439.PubMed
21.
Zurück zum Zitat He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants Maintain Cellular Redox Homeostasis by Elimination of Reactive Oxygen Species. Cell Physiol Biochem. 2017;44:532–53.PubMed He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants Maintain Cellular Redox Homeostasis by Elimination of Reactive Oxygen Species. Cell Physiol Biochem. 2017;44:532–53.PubMed
22.
Zurück zum Zitat Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47–95.PubMed Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47–95.PubMed
23.
Zurück zum Zitat Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1–40.PubMed Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1–40.PubMed
24.
Zurück zum Zitat Bhat AH, Dar KB, Anees S, Zargar MA, Masood A, Sofi MA, et al. Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomed Pharmacother. 2007;74:101–10. Bhat AH, Dar KB, Anees S, Zargar MA, Masood A, Sofi MA, et al. Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomed Pharmacother. 2007;74:101–10.
25.
Zurück zum Zitat Fraternale A, Zara C, De Angelis M, Nencioni L, Palamara AT, Retini M, et al. Intracellular redox-modulated pathways as targets for effective approaches in the treatment of viral infection. Int J Mol Sci. 2021;22:3603.PubMedPubMedCentral Fraternale A, Zara C, De Angelis M, Nencioni L, Palamara AT, Retini M, et al. Intracellular redox-modulated pathways as targets for effective approaches in the treatment of viral infection. Int J Mol Sci. 2021;22:3603.PubMedPubMedCentral
26.
Zurück zum Zitat Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV. Redox biology of respiratory viral infections. Viruses. 2018;10:392.PubMedPubMedCentral Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV. Redox biology of respiratory viral infections. Viruses. 2018;10:392.PubMedPubMedCentral
27.
Zurück zum Zitat Hosakote YM, Liu T, Castro SM, Garofalo RP, Casola A. Respiratory syncytial virus induces oxidative stress by modulating antioxidant enzymes. Am J Respir Cell Mol Biol. 2009;41:348–57.PubMedPubMedCentral Hosakote YM, Liu T, Castro SM, Garofalo RP, Casola A. Respiratory syncytial virus induces oxidative stress by modulating antioxidant enzymes. Am J Respir Cell Mol Biol. 2009;41:348–57.PubMedPubMedCentral
28.
Zurück zum Zitat Komaravelli N, Tian B, Ivanciuc T, Mautemps N, Brasier AR, Garofalo RP, et al. Respiratory syncytial virus infection down-regulates antioxidant enzyme expression by triggering deacetylation-proteasomal degradation of Nrf2. Free Radic Biol Med. 2015;88:391–403.PubMedPubMedCentral Komaravelli N, Tian B, Ivanciuc T, Mautemps N, Brasier AR, Garofalo RP, et al. Respiratory syncytial virus infection down-regulates antioxidant enzyme expression by triggering deacetylation-proteasomal degradation of Nrf2. Free Radic Biol Med. 2015;88:391–403.PubMedPubMedCentral
29.
Zurück zum Zitat Sorrentino L, Toscanelli W, Fracella M, De Angelis M, Frasca F, Scagnolari C, et al. NRF2 antioxidant response and interferon-stimulated genes are differentially expressed in respiratory-syncytial-virus- and rhinovirus-infected hospitalized children. Pathogens. 2023;12:577.PubMed Sorrentino L, Toscanelli W, Fracella M, De Angelis M, Frasca F, Scagnolari C, et al. NRF2 antioxidant response and interferon-stimulated genes are differentially expressed in respiratory-syncytial-virus- and rhinovirus-infected hospitalized children. Pathogens. 2023;12:577.PubMed
30.
Zurück zum Zitat De Angelis M, Amatore D, Checconi P, Zevini A, Fraternale A, Magnani M, et al. Influenza virus down-modulates G6PD expression and activity to induce oxidative stress and promote its replication. Front Cell Infect Microbiol. 2022;11:804976. De Angelis M, Amatore D, Checconi P, Zevini A, Fraternale A, Magnani M, et al. Influenza virus down-modulates G6PD expression and activity to induce oxidative stress and promote its replication. Front Cell Infect Microbiol. 2022;11:804976.
31.
Zurück zum Zitat Polonikov A. Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infect Dis. 2020;6:1558–62.PubMed Polonikov A. Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infect Dis. 2020;6:1558–62.PubMed
32.
Zurück zum Zitat Schönrich G, Raftery MJ, Samstag Y. Devilishly radical NETwork in COVID-19: oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. Adv Biol Regul. 2020;77:100741.PubMedCentral Schönrich G, Raftery MJ, Samstag Y. Devilishly radical NETwork in COVID-19: oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. Adv Biol Regul. 2020;77:100741.PubMedCentral
33.
Zurück zum Zitat Bartolini D, Stabile AM, Bastianelli S, Giustarini D, Pierucci S, Busti C, et al. SARS-CoV2 infection impairs the metabolism and redox function of cellular glutathione. Redox Biol. 2021;45:102041.PubMedPubMedCentral Bartolini D, Stabile AM, Bastianelli S, Giustarini D, Pierucci S, Busti C, et al. SARS-CoV2 infection impairs the metabolism and redox function of cellular glutathione. Redox Biol. 2021;45:102041.PubMedPubMedCentral
34.
Zurück zum Zitat Olagnier D, Farahani E, Thyrsted J, Blay-Cadanet J, Herengt A, Idorn M, et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun. 2020;11:4938.PubMedPubMedCentral Olagnier D, Farahani E, Thyrsted J, Blay-Cadanet J, Herengt A, Idorn M, et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun. 2020;11:4938.PubMedPubMedCentral
35.
Zurück zum Zitat Qu Y, de Mello AH, Morris DR, Jones-Hall YL, Ivanciuc T, Sattler RA, et al. SARS-CoV-2 inhibits NRF2-mediated antioxidant responses in airway epithelial cells and in the lung of a murine model of infection. Microbiol Spectr. 2023;6:e0037823. Qu Y, de Mello AH, Morris DR, Jones-Hall YL, Ivanciuc T, Sattler RA, et al. SARS-CoV-2 inhibits NRF2-mediated antioxidant responses in airway epithelial cells and in the lung of a murine model of infection. Microbiol Spectr. 2023;6:e0037823.
36.
Zurück zum Zitat Cuadrado A, Pajares M, Benito C, Jiménez-Villegas J, Escoll M, Fernández-Ginés R, et al. Can activation of NRF2 be a strategy against COVID-19? Trends Pharmacol Sci. 2020;41:598–610.PubMedPubMedCentral Cuadrado A, Pajares M, Benito C, Jiménez-Villegas J, Escoll M, Fernández-Ginés R, et al. Can activation of NRF2 be a strategy against COVID-19? Trends Pharmacol Sci. 2020;41:598–610.PubMedPubMedCentral
37.
Zurück zum Zitat Herengt A, Thyrsted J, Holm CK. NRF2 in viral infection. Antioxidants (Basel). 2021;10:1491.PubMed Herengt A, Thyrsted J, Holm CK. NRF2 in viral infection. Antioxidants (Basel). 2021;10:1491.PubMed
38.
Zurück zum Zitat Mastrantonio R, Cervelli M, Pietropaoli S, Mariottini P, Colasanti M, Persichini T. HIV-Tat induces the Nrf2/ARE pathway through NMDA receptor-elicited spermine oxidase activation in human neuroblastoma cells. PLoS ONE. 2016;11:e0149802.PubMedPubMedCentral Mastrantonio R, Cervelli M, Pietropaoli S, Mariottini P, Colasanti M, Persichini T. HIV-Tat induces the Nrf2/ARE pathway through NMDA receptor-elicited spermine oxidase activation in human neuroblastoma cells. PLoS ONE. 2016;11:e0149802.PubMedPubMedCentral
39.
Zurück zum Zitat Choi Y, Jiang Z, Shin WJ, Jung JU. Severe fever with thrombocytopenia syndrome virus nss interacts with TRIM21 to activate the p62-Keap1-Nrf2 pathway. J Virol. 2020;94:e01684-e1719.PubMedPubMedCentral Choi Y, Jiang Z, Shin WJ, Jung JU. Severe fever with thrombocytopenia syndrome virus nss interacts with TRIM21 to activate the p62-Keap1-Nrf2 pathway. J Virol. 2020;94:e01684-e1719.PubMedPubMedCentral
40.
Zurück zum Zitat Kuzmenko YV, Smirnova OA, Ivanov AV, Starodubova ES, Karpov VL. Nonstructural protein 1 of tick-borne encephalitis virus induces oxidative stress and activates antioxidant defense by the Nrf2/ARE pathway. Intervirology. 2016;59:111–7.PubMed Kuzmenko YV, Smirnova OA, Ivanov AV, Starodubova ES, Karpov VL. Nonstructural protein 1 of tick-borne encephalitis virus induces oxidative stress and activates antioxidant defense by the Nrf2/ARE pathway. Intervirology. 2016;59:111–7.PubMed
42.
Zurück zum Zitat Nencioni L, Iuvara A, Aquilano K, Ciriolo MR, Cozzolino F, Rotilio G, et al. Influenza A virus replication is dependent on an antioxidant pathway that involves GSH and Bcl-2. FASEB J. 2003;17:758–60.PubMed Nencioni L, Iuvara A, Aquilano K, Ciriolo MR, Cozzolino F, Rotilio G, et al. Influenza A virus replication is dependent on an antioxidant pathway that involves GSH and Bcl-2. FASEB J. 2003;17:758–60.PubMed
43.
Zurück zum Zitat Nencioni L, De Chiara G, Sgarbanti R, Amatore D, Aquilano K, Marcocci ME, et al. Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication. J Biol Chem. 2009;284:16004–15.PubMed Nencioni L, De Chiara G, Sgarbanti R, Amatore D, Aquilano K, Marcocci ME, et al. Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication. J Biol Chem. 2009;284:16004–15.PubMed
44.
Zurück zum Zitat Cecchini R, Cecchini AL. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med Hypotheses. 2020;143:110102.PubMedPubMedCentral Cecchini R, Cecchini AL. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression. Med Hypotheses. 2020;143:110102.PubMedPubMedCentral
45.
Zurück zum Zitat Derouiche S. Oxidative stress associated with SARS-Cov-2 (COVID-19) increases the severity of the lung disease-a systematic review. J Infect Dis Epidemiol. 2020;6:121. Derouiche S. Oxidative stress associated with SARS-Cov-2 (COVID-19) increases the severity of the lung disease-a systematic review. J Infect Dis Epidemiol. 2020;6:121.
46.
Zurück zum Zitat Laforge M, Elbim C, Frère C, Hémadi M, Massaad C, Nuss P, et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol. 2020;20:515–6.PubMedPubMedCentral Laforge M, Elbim C, Frère C, Hémadi M, Massaad C, Nuss P, et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol. 2020;20:515–6.PubMedPubMedCentral
47.
Zurück zum Zitat Walter M, Chen IP, Vallejo-Gracia A, Kim IJ, Bielska O, Lam VL, et al. SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein. BioRxiv. 2022;5:2022.01.04.474979. Walter M, Chen IP, Vallejo-Gracia A, Kim IJ, Bielska O, Lam VL, et al. SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein. BioRxiv. 2022;5:2022.01.04.474979.
48.
Zurück zum Zitat Zhang S, Wang J, Wang L, Aliyari S, Cheng G. SARS-CoV-2 virus NSP14 Impairs NRF2/HMOX1 activation by targeting Sirtuin 1. Cell Mol Immunol. 2022;19:872–82.PubMedPubMedCentral Zhang S, Wang J, Wang L, Aliyari S, Cheng G. SARS-CoV-2 virus NSP14 Impairs NRF2/HMOX1 activation by targeting Sirtuin 1. Cell Mol Immunol. 2022;19:872–82.PubMedPubMedCentral
49.
Zurück zum Zitat Gunderstofte C, Iversen MB, Peri S, Thielke A, Balachandran S, Holm CK, et al. Nrf2 negatively regulates type i interferon responses and increases susceptibility to herpes genital infection in mice. Front Immunol. 2019;10:2101.PubMedPubMedCentral Gunderstofte C, Iversen MB, Peri S, Thielke A, Balachandran S, Holm CK, et al. Nrf2 negatively regulates type i interferon responses and increases susceptibility to herpes genital infection in mice. Front Immunol. 2019;10:2101.PubMedPubMedCentral
50.
Zurück zum Zitat Olagnier D, Brandtoft AM, Gunderstofte C, Villadsen NL, Krapp C, Thielke AL, et al. Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming. Nat Commun. 2018;9:3506.PubMedPubMedCentral Olagnier D, Brandtoft AM, Gunderstofte C, Villadsen NL, Krapp C, Thielke AL, et al. Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming. Nat Commun. 2018;9:3506.PubMedPubMedCentral
51.
Zurück zum Zitat Gori Savellini G, Anichini G, Gandolfo C, Cusi MG. Nucleopore traffic is hindered by SARS-CoV-2 ORF6 protein to efficiently suppress IFN-β and IL-6 secretion. Viruses. 2022;14:1273.PubMedPubMedCentral Gori Savellini G, Anichini G, Gandolfo C, Cusi MG. Nucleopore traffic is hindered by SARS-CoV-2 ORF6 protein to efficiently suppress IFN-β and IL-6 secretion. Viruses. 2022;14:1273.PubMedPubMedCentral
52.
Zurück zum Zitat Miorin L, Kehrer T, Sanchez-Aparicio MT, Zhang K, Cohen P, Patel RS, et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci USA. 2020;117:28344–54.PubMed Miorin L, Kehrer T, Sanchez-Aparicio MT, Zhang K, Cohen P, Patel RS, et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci USA. 2020;117:28344–54.PubMed
53.
Zurück zum Zitat Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.PubMedPubMedCentral Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.PubMedPubMedCentral
54.
Zurück zum Zitat Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-Nrf2 Interaction in Non-Small-Cell Lung Cancer. PLoS Med. 2006;3:e420.PubMedPubMedCentral Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, et al. Dysfunctional KEAP1-Nrf2 Interaction in Non-Small-Cell Lung Cancer. PLoS Med. 2006;3:e420.PubMedPubMedCentral
55.
Zurück zum Zitat Liu T, Lv YF, Zhao JL, You QD, Jiang ZY. Regulation of Nrf2 by phosphorylation: Consequences for biological function and therapeutic implications. Free Radic Biol Med. 2021;168:129–41.PubMed Liu T, Lv YF, Zhao JL, You QD, Jiang ZY. Regulation of Nrf2 by phosphorylation: Consequences for biological function and therapeutic implications. Free Radic Biol Med. 2021;168:129–41.PubMed
56.
Zurück zum Zitat Salazar M, Rojo AI, Velasco D, de Sagarra RM, Cuadrado A. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem. 2006;281:14841–51.PubMed Salazar M, Rojo AI, Velasco D, de Sagarra RM, Cuadrado A. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem. 2006;281:14841–51.PubMed
57.
Zurück zum Zitat Reichard JF, Motz GT, Puga A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res. 2007;35:7074–86.PubMedPubMedCentral Reichard JF, Motz GT, Puga A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res. 2007;35:7074–86.PubMedPubMedCentral
58.
Zurück zum Zitat Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol. 2011;31:1121–33.PubMedPubMedCentral Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol. 2011;31:1121–33.PubMedPubMedCentral
59.
Zurück zum Zitat Yuan X, Xu C, Pan Z, Keum YS, Kim JH, Shen G, et al. Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. Mol Carcinog. 2006;45:841–50. Yuan X, Xu C, Pan Z, Keum YS, Kim JH, Shen G, et al. Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. Mol Carcinog. 2006;45:841–50.
60.
Zurück zum Zitat Ma L, Liu J, Zhang X, Qi J, Yu W, Gu Y. p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ. Med Oncol. 2015;32:69.PubMed Ma L, Liu J, Zhang X, Qi J, Yu W, Gu Y. p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ. Med Oncol. 2015;32:69.PubMed
61.
Zurück zum Zitat Naidu S, Vijayan V, Santoso S, Kietzmann T, Immenschuh S. Inhibition and genetic deficiency of p38 MAPK up-regulates heme oxygenase-1 gene expression via Nrf2. J Immunol. 2009;182:7048–57.PubMed Naidu S, Vijayan V, Santoso S, Kietzmann T, Immenschuh S. Inhibition and genetic deficiency of p38 MAPK up-regulates heme oxygenase-1 gene expression via Nrf2. J Immunol. 2009;182:7048–57.PubMed
62.
Zurück zum Zitat Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133:235–49.PubMedPubMedCentral Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133:235–49.PubMedPubMedCentral
63.
Zurück zum Zitat Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19:181–93.PubMedPubMedCentral Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19:181–93.PubMedPubMedCentral
64.
Zurück zum Zitat Addetia A, Lieberman NAP, Phung Q, Hsiang TY, Xie H, Roychoudhury P, et al. SARS-CoV-2 ORF6 disrupts bidirectional nucleocytoplasmic transport through interactions with Rae1 and Nup98. mBio. 2021;12:e00065-21.PubMedPubMedCentral Addetia A, Lieberman NAP, Phung Q, Hsiang TY, Xie H, Roychoudhury P, et al. SARS-CoV-2 ORF6 disrupts bidirectional nucleocytoplasmic transport through interactions with Rae1 and Nup98. mBio. 2021;12:e00065-21.PubMedPubMedCentral
65.
Zurück zum Zitat Min YQ, Huang M, Sun X, Deng F, Wang H, Ning YJ. Immune evasion of SARS-CoV-2 from interferon antiviral system. Comput Struct Biotechnol J. 2021;19:4217–25.PubMedPubMedCentral Min YQ, Huang M, Sun X, Deng F, Wang H, Ning YJ. Immune evasion of SARS-CoV-2 from interferon antiviral system. Comput Struct Biotechnol J. 2021;19:4217–25.PubMedPubMedCentral
66.
Zurück zum Zitat Abdalla AE, Xie J, Junaid K, Younas S, Elsaman T, Abosalif KOA, et al. Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense. Bosn J Basic Med Sci. 2020;21:515–27. Abdalla AE, Xie J, Junaid K, Younas S, Elsaman T, Abosalif KOA, et al. Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense. Bosn J Basic Med Sci. 2020;21:515–27.
67.
Zurück zum Zitat Hossain A, Akter S, Rashid AA, Khair S, Alam A. Unique mutations in SARS-CoV-2 Omicron subvariants’ non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion. Microb Pathog. 2022;170:105699.PubMed Hossain A, Akter S, Rashid AA, Khair S, Alam A. Unique mutations in SARS-CoV-2 Omicron subvariants’ non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion. Microb Pathog. 2022;170:105699.PubMed
68.
Zurück zum Zitat Yuen CK, Lam JY, Wong WM, Mak LF, Wang X, Chu H, et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect. 2020;9:1418–28.PubMedPubMedCentral Yuen CK, Lam JY, Wong WM, Mak LF, Wang X, Chu H, et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect. 2020;9:1418–28.PubMedPubMedCentral
69.
Zurück zum Zitat Schwarz KB. Oxidative stress during viral infection: a review. Free Radic Biol Med. 1996;21:641–9.PubMed Schwarz KB. Oxidative stress during viral infection: a review. Free Radic Biol Med. 1996;21:641–9.PubMed
70.
Zurück zum Zitat Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med. 2004;36:1199–207.PubMed Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med. 2004;36:1199–207.PubMed
71.
Zurück zum Zitat Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem. 2004;279:8919–29.PubMed Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem. 2004;279:8919–29.PubMed
72.
Zurück zum Zitat Yu R, Lei W, Mandlekar S, Weber MJ, Der CJ, Wu J, et al. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J Biol Chem. 1999;274:27545–52.PubMed Yu R, Lei W, Mandlekar S, Weber MJ, Der CJ, Wu J, et al. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J Biol Chem. 1999;274:27545–52.PubMed
73.
Zurück zum Zitat Lauretti E, Dincer O, Praticò D. Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res. 2020;1867:118664.PubMedPubMedCentral Lauretti E, Dincer O, Praticò D. Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res. 2020;1867:118664.PubMedPubMedCentral
74.
Zurück zum Zitat Jain AK, Jaiswal AK. GSK-3β acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem. 2007;282:16502–10.PubMed Jain AK, Jaiswal AK. GSK-3β acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem. 2007;282:16502–10.PubMed
75.
Zurück zum Zitat McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ. Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. Int J Mol Med. 2007;19:165–72.PubMed McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ. Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition. Int J Mol Med. 2007;19:165–72.PubMed
76.
Zurück zum Zitat Rojo AI, Medina-Campos ON, Rada P, Zúñiga-Toalá A, López-Gazcón A, Espada S, et al. Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: role of glycogen synthase kinase-3. Free Radic Biol Med. 2012;52:473–87.PubMed Rojo AI, Medina-Campos ON, Rada P, Zúñiga-Toalá A, López-Gazcón A, Espada S, et al. Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-independent regulation of Nrf2 stability: role of glycogen synthase kinase-3. Free Radic Biol Med. 2012;52:473–87.PubMed
77.
Zurück zum Zitat Steinberg SF. Mechanisms for redox-regulation of protein kinase C. Front Pharm. 2012;6:128. Steinberg SF. Mechanisms for redox-regulation of protein kinase C. Front Pharm. 2012;6:128.
78.
Zurück zum Zitat Bloom DA, Jaiswal AK. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem. 2003;278:44675–82.PubMed Bloom DA, Jaiswal AK. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem. 2003;278:44675–82.PubMed
79.
Zurück zum Zitat McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal. 2006;8:1775–89.PubMed McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal. 2006;8:1775–89.PubMed
80.
Zurück zum Zitat Keum YS, Yu S, Chang PP, Yuan X, Kim JH, Xu C, et al. Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res. 2006;66:8804–13.PubMed Keum YS, Yu S, Chang PP, Yuan X, Kim JH, Xu C, et al. Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res. 2006;66:8804–13.PubMed
81.
Zurück zum Zitat Grimes JM, Grimes KV. p38 MAPK inhibition: a promising therapeutic approach for COVID-19. J Mol Cell Cardiol. 2020;144:63–5.PubMedPubMedCentral Grimes JM, Grimes KV. p38 MAPK inhibition: a promising therapeutic approach for COVID-19. J Mol Cell Cardiol. 2020;144:63–5.PubMedPubMedCentral
82.
Zurück zum Zitat Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem. 2002;277:42769–74.PubMed Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem. 2002;277:42769–74.PubMed
83.
Zurück zum Zitat Mihaylova VT, Kong Y, Fedorova O, Sharma L, Dela Cruz CS, Pyle AM, et al. Regional differences in airway epithelial cells reveal tradeoff between defense against oxidative stress and defense against rhinovirus. Cell Rep. 2018;24:3000–7.PubMedPubMedCentral Mihaylova VT, Kong Y, Fedorova O, Sharma L, Dela Cruz CS, Pyle AM, et al. Regional differences in airway epithelial cells reveal tradeoff between defense against oxidative stress and defense against rhinovirus. Cell Rep. 2018;24:3000–7.PubMedPubMedCentral
Metadaten
Titel
Dysregulation of intracellular redox homeostasis by the SARS-CoV-2 ORF6 protein
verfasst von
Marta De Angelis
Gabriele Anichini
Anna Teresa Palamara
Lucia Nencioni
Gianni Gori Savellini
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
Virology Journal / Ausgabe 1/2023
Elektronische ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02208-7

Weitere Artikel der Ausgabe 1/2023

Virology Journal 1/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.